Bio

Biographical Sketch:
Dr. Stupp received his medical degree from Zurich University Medical School, Zurich, Switzerland. He completed training in internal medicine at the Langenthal/Bern County Hospital and the University Hospital of Zurich. In pursuing and completing specialization in hematology and oncology, he spent 3 years as a fellow in medicine and hematology/oncology at the University of Chicago Hospitals and Cancer Center in Illinois. In his current position with the Department of Neurosurgery of the University of Lausanne Medical Center (CHUV), he leads the multidisciplinary brain tumor clinic.

Dr. Stupp is an active and dedicated clinical researcher. His special clinical interests include the multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers, as well as new drug development and the association of chemotherapy and radiation therapy. He is also closely involved in bringing new antiangiogenic and biological treatments to the clinic. Dr. Stupp maintains close collaborations with the Laboratory of Tumor Biology and Genetics at the CHUV, the Laboratory of Tumor Angiogenesis and Melanoma Research, and the Swiss Institute of Experimental Cancer Research (ISREC).

Dr. Stupp has been the lead investigator for establishing the use of temozolomide chemotherapy in conjunction with radiotherapy in newly diagnosed glioblastoma and determining the predictive value of MGMT gene-promoter methylation. Recent work includes the association of the integrin inhibitor cilengitide in addition to chemoradiotherapy, currently under investigation in a randomized phase III trial. He co-chairs several randomized clinical trials, including EORTC 22033-26033, comparing primary chemotherapy versus radiotherapy in patients with low-grade glioma, and trials on novel agents or modalities in patients with recurrent glioma.

Head and neck tumors and lung cancer are other areas of research interest. On behalf of the Swiss Group for Clinical Cancer Research (SAKK), Dr. Stupp recently reported on a curative approach for treating locally advanced, “inoperable” stage IIIB non−small cell lung cancer (NSCLC) with neoadjuvant chemotherapy and radiotherapy, followed by definitive surgery. This approach is currently under in investigation in a randomized phase III trial being conducted by the SAKK for patients with stage IIIA NSCLC.

Dr. Stupp serves as vice president for the European Organization for Research and Treatment of Cancer (EORTC) and is a member of the executive committee. He is the past secretary of the Brain Tumor Group.

Dr. Stupp serves on the editorial boards of numerous journals in his field, including the Journal of Clinical Oncology and Neuro-Oncology.

Positions:
Head, Department of Oncology of the Riveria/Chablais region at the hospitals of Vevey and Monthey, Switzerland; attending physician at the Department of Neurosurgery of the University of Lausanne Medical Center (CHUV)

Degrees:
Zurich University Medical School, Zurich, Switzerland

Postgraduate Training:
Langenthal/Bern County Hospital and the University Hospital of Zurich; fellowship in medicine and hematology/oncology at the University of Chicago Hospitals and Cancer Center in Illinois

Clinical Interests:
Multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers; new drug development and the association of chemotherapy and radiation therapy; head and neck tumors; lung cancer